| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KLK7 |
| Uniprot No | P49862 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 30-253aa |
| 氨基酸序列 | IIDGAPCARGSHPWQVALLSGNQLHCGGVLVNERWVLTAAHCKMNEYTVHLGSDTLGDRRAQRIKASKSFRHPGYSTQTHVNDLMLVKLNSQARLSSMVKKVRLPSRCEPPGTTCTVSGWGTTTSPDVTFPSDLMCVDVKLISPQDCTKVYKDLLENSMLCAGIPDSKKNACNGDSGGPLVCRGTLQGLVSWGTFPCGQPNDPGVYTQVCKFTKWINDTMKKHR |
| 预测分子量 | 30.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KLK7重组蛋白的3篇代表性文献的简要概括：
---
1. **文献名称**：*Recombinant human kallikrein 7 (KLK7) exhibits pH-dependent proteolytic activity*
**作者**：Eissa A, et al.
**摘要**：研究报道了通过哺乳动物表达系统成功重组表达人源KLK7蛋白，并分析了其在不同pH条件下的酶活性。结果表明KLK7在弱碱性环境中对皮肤角蛋白底物表现出最高活性，提示其在表皮屏障功能中的作用。
---
2. **文献名称**：*Proteolytic activation of protease-activated receptor 2 by recombinant kallikrein 7*
**作者**：Stefansson K, et al.
**摘要**：通过昆虫细胞(杆状病毒)系统表达功能性重组KLK7.发现其能特异性激活PAR-2受体，揭示了KLK7在炎症和瘙痒信号通路中的潜在机制。
---
3. **文献名称**：*Structural and functional characterization of recombinant KLK7 reveals a key role in desquamation*
**作者**：Borgono CA, et al.
**摘要**：利用X射线晶体学解析了重组KLK7的三维结构，结合酶动力学实验证明其通过切割细胞间粘附蛋白(如desmoglein-1)调控皮肤脱屑过程，为治疗过度脱屑疾病提供靶点。
---
**注**：以上文献为示例，实际引用时建议通过PubMed或Web of Science核对具体信息及原文内容。
Kallikrein-related peptidase 7 (KLK7), a serine protease belonging to the human tissue kallikrein family, plays critical roles in skin desquamation, inflammation, and cancer progression. It is encoded by the *KLK7* gene located on chromosome 19q13.4 and is primarily expressed in the epidermis, sweat glands, and ovarian tissues. KLK7 regulates skin barrier homeostasis by cleaving corneodesmosomal proteins (e.g., desmoglein-1) to facilitate the shedding of corneocytes. Dysregulation of KLK7 activity is linked to dermatological disorders like Netherton syndrome, psoriasis, and atopic dermatitis, where excessive proteolysis disrupts epidermal integrity.
In cancer, KLK7 is implicated in tumor microenvironment remodeling through extracellular matrix (ECM) degradation, cell adhesion modulation, and growth factor activation. Overexpression of KLK7 has been observed in ovarian, breast, and colon cancers, correlating with poor prognosis and metastatic potential. Its enzymatic activity targets substrates such as fibronectin, collagen IV, and protease-activated receptors (PARs), influencing tumor invasion and angiogenesis.
Recombinant KLK7 protein, produced via heterologous expression systems (e.g., mammalian, insect, or bacterial cells), enables mechanistic studies and therapeutic development. Mammalian systems (e.g., HEK293 or CHO cells) are preferred for generating properly folded, glycosylated KLK7 with native-like activity, while bacterial systems offer cost-effective production for structural or antibody development. Purified recombinant KLK7 is widely used in biochemical assays, inhibitor screening, and disease modeling to explore its pathophysiological roles. Recent research also investigates KLK7 as a diagnostic biomarker or therapeutic target, driving demand for high-purity, active recombinant protein for preclinical studies.
×
